Evidence map›Paper›PMID 34508864›Full record

ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2021

Antimicrobial resistance: A challenge awaiting the post-COVID-19 era.

Tekle Airgecho Lobie, Aklilu Abrham Roba, James Alexander Booth, Knut Ivan Kristiansen, Abraham Aseffa, Kirsten Skarstad, Magnar Bjørås

Open access · goldAbstract read
In one paragraph

Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 55 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Key attributes of health and environmental risk decision-making: A scoping review.Risk analysis : an official publication of the Society for Risk Analysis · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Biological investigation ofJournal of enzyme inhibition and medicinal chemistry · 2022
    Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Tekle Airgecho LobieDepartment of Microbiology, University of Oslo and Oslo University Hospital, Rikshospitalet, Oslo, Norway. Electronic address: teklemicro@gmail.com.
Aklilu Abrham RobaCollege of Health and Medical Sciences, Haramaya University, Harar, Ethiopia.
James Alexander BoothDepartment of Microbiology, University of Oslo and Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Knut Ivan KristiansenDepartment of Microbiology, University of Oslo and Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Abraham AseffaArmauer Hansen Research Institute, Addis Ababa, Ethiopia.
Kirsten SkarstadDepartment of Microbiology, University of Oslo and Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Magnar BjøråsDepartment of Microbiology, University of Oslo and Oslo University Hospital, Rikshospitalet, Oslo, Norway; Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
Oslo University Hospital · NOArmauer Hansen Research Institute · ETHaramaya University · ET

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microbe exposure to pharmaceutical and non-pharmaceutical agents plays a role in the development of antibiotic resistance. The risks and consequences associated with extensive disinfectant use during the COVID-19 pandemic remain unclear. Some disinfectants, like sanitizers, contain genotoxic chemicals that damage microbial DNA, like phenol and hydrogen peroxide. This damage activates error-prone DNA repair enzymes, which can lead to mutations that induce antimicrobial resistance. Public health priority programs that have faced drug-resistance challenges associated with diseases, such as tuberculosis, HIV, and malaria, have given less attention to risks attributable to the COVID-19 pandemic. Pathogen-specific programs, like the directly observed treatment strategy designed to fight resistance against anti-tuberculosis drugs, have become impractical because COVID-19 restrictions have limited in-person visits to health institutions. Here, we summarized the key findings of studies on the current state of antimicrobial resistance development from the perspective of current disinfectant use. Additionally, we provide a brief overview of the consequences of restricted access to health services due to COVID-19 precautions and their implications on drug resistance development.

Indexed as

COVID-19Drug Resistance, BacterialAnti-Bacterial AgentsAntitubercular AgentsHumansPandemicsSARS-CoV-2Anti-Bacterial AgentsAntitubercular AgentsAMRBacteriaCOVID-19Disinfectantsnon-pharmaceuticalspharmaceuticals

Identifiers

PMID34508864
PMCPMC8425743
OpenAlexW3198408315

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.